<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04603989</url>
  </required_header>
  <id_info>
    <org_study_id>HNC042-102</org_study_id>
    <secondary_id>ZBD1042-CSP01</secondary_id>
    <nct_id>NCT04603989</nct_id>
  </id_info>
  <brief_title>A Study of HNC042 in Healthy Chinese Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Sequential Parallel Group, Multiple Ascending Doses Study Following Intravenous Administration in Healthy Chinese Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of HNC042</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Henovcom Bioscience Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangzhou Henovcom Bioscience Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety , tolerability and pharmacokinetics after&#xD;
      multiple ascending of HNC042 given to healthy Chinese volunteers, compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2020</start_date>
  <completion_date type="Anticipated">October 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 18, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with abnormal vital signs</measure>
    <time_frame>Between screening and 15 days after the last dose</time_frame>
    <description>To evaluate the safety and tolerability of HNC042 in comparison with placebo after multiple intravenous dose in healthy Chinese subjects in terms of abnormal vital signs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal laboratory</measure>
    <time_frame>Between screening and 15 days after the last dose</time_frame>
    <description>To evaluate the safety and tolerability of HNC042 in comparison with placebo after multiple intravenous dose in healthy Chinese subjects in terms of abnormal laboratory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal electrocardiogram</measure>
    <time_frame>Between screening and 15 days after the last dose</time_frame>
    <description>To evaluate the safety and tolerability of HNC042 in comparison with placebo after multiple intravenous dose in healthy Cjinese subjects in terms of abnormal electrocardiogram</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal physical examination</measure>
    <time_frame>Between screening and 15 days after the last dose</time_frame>
    <description>To evaluate the safety and tolerability of HNC042 in comparison with placebo after multiple intravenous dose in healthy Cjinese subjects in terms of abnormal physical examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with adverse reactions at injection site</measure>
    <time_frame>Between screening and 15 days after the last dose</time_frame>
    <description>To evaluate the safety and tolerability of HNC042 in comparison with placebo after multiple intravenous dose in healthy Cjinese subjects in terms of adverse reactions at injection site</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>Between screening and 15 days after the last dose</time_frame>
    <description>To evaluate the safety and tolerability of HNC042 in comparison with placebo after multiple intravenous dose in healthy Cjinese subjects in terms of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinical symptoms</measure>
    <time_frame>Between screening and 15 days after the last dose</time_frame>
    <description>To evaluate the safety and tolerability of HNC042 in comparison with placebo after multiple intravenous dose in healthy Cjinese subjects in terms of clinical symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of HNC042 in plasma: Cmax</measure>
    <time_frame>Between Day 1 to 7 days</time_frame>
    <description>To characterize the pharmacokinetic parameters：Cmax of HNC042 after the the first day administer .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of HNC042 in plasma: Tmax</measure>
    <time_frame>Between Day 1 to 7 days</time_frame>
    <description>To characterize the pharmacokinetic parameters：Tmax of HNC042 after the the first day administer .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of HNC042 in plasma: AUC0-last</measure>
    <time_frame>Between Day 1 to 7 days</time_frame>
    <description>To characterize the pharmacokinetic parameters：AUC0-last of HNC042 after the the first day administer .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of HNC042 in plasma: AUC0-∞</measure>
    <time_frame>Between Day 1 to 7 days</time_frame>
    <description>To characterize the pharmacokinetic parameters： AUC0-∞ of HNC042 after the the first day administer .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of HNC042 in plasma:t1/2</measure>
    <time_frame>Between Day 1 to 7 days</time_frame>
    <description>To characterize the pharmacokinetic parameters： t1/2 of HNC042 after the the first day administer .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of HNC042 in plasma:MRT</measure>
    <time_frame>Between Day 1 to 7 days</time_frame>
    <description>To characterize the pharmacokinetic parameters： MRT of HNC042 after the the first day administer .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of HNC042 in plasma:CL</measure>
    <time_frame>Between Day 1 to 7 days</time_frame>
    <description>To characterize the pharmacokinetic parameters：CL of HNC042 after the the first day administer .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of HNC042 in plasma:Vd</measure>
    <time_frame>Between Day 1 to 7 days</time_frame>
    <description>To characterize the pharmacokinetic parameters：Vd of HNC042 after the the first day administer .</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>HNC042</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HNC4042 for injection,freeze-dried powder,multiple ascending doses, Intravenous route</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, multiple ascending doses, Intravenous route</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HNC042 for Injection</intervention_name>
    <description>HNC042,freeze-dried powder,multiple ascending doses, Intravenous route Multiple doses, daily for 7 days, doses: 300mg to 1200mg</description>
    <arm_group_label>HNC042</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>Placebo , Intravenous route , multiple ascending doses</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  volunteers can communicate well with the investigator, understand and comply with the&#xD;
             relevant requirements of the study, understand and sign the informed consent&#xD;
&#xD;
          -  Healthy adult male or female volunteers, age 18-65 years，&#xD;
&#xD;
          -  BMI between 19-26 kg/m2,and male body weight not less than 50.0kg,female body weight&#xD;
             not less than 45.0kg .&#xD;
&#xD;
          -  volunteers with normal renal function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any condition that might interfere with the procedures or tests in this study&#xD;
&#xD;
          -  Drug or alcohol abuse&#xD;
&#xD;
          -  Smoking&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lu Xiang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sir Run Run Hospital, Nanjing Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jiang Yuting</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiang Yuting</last_name>
      <phone>020-32039103</phone>
      <email>yutingjiang@henovcom.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 13, 2020</study_first_submitted>
  <study_first_submitted_qc>October 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2020</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neuraminidase inhibitor</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

